Hops (Humulus lupulus) inhibits oxidative estrogen metabolism and estrogen-induced malignant transformation in human mammary epithelial cells (MCF-10A). 2012

L P Hemachandra, and P Madhubhani, and R Chandrasena, and P Esala, and Shao-Nong Chen, and Matthew Main, and David C Lankin, and Robert A Scism, and Birgit M Dietz, and Guido F Pauli, and Gregory R J Thatcher, and Judy L Bolton
Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street, Chicago, IL 60612-7231, USA.

Long-term exposure to estrogens including those in traditional hormone replacement therapy (HRT) increases the risk of developing hormone-dependent cancers. As a result, women are turning to over-the-counter (OTC) botanical dietary supplements, such as black cohosh (Cimicifuga racemosa) and hops (Humulus lupulus), as natural alternatives to HRT. The two major mechanisms which likely contribute to estrogen and/or HRT cancer risk are: the estrogen receptor-mediated hormonal pathway; and the chemical carcinogenesis pathway involving formation of estrogen quinones that damage DNA and proteins, hence initiating and promoting carcinogenesis. Because, OTC botanical HRT alternatives are in widespread use, they may have the potential for chemopreventive effects on estrogen carcinogenic pathways in vivo. Therefore, the effect of OTC botanicals on estrogen-induced malignant transformation of MCF-10A cells was studied. Cytochrome P450 catalyzed hydroxylation of estradiol at the 4-position leads to an o-quinone believed to act as the proximal carcinogen. Liquid chromatography/tandem mass spectrometry analysis of estradiol metabolites showed that 4-hydroxylation was inhibited by hops, whereas black cohosh was without effect. Estrogen-induced expression of CYP450 1B1 and CYP450 1A1 was attenuated by the hops extract. Two phenolic constituents of hops (xanthohumol, XH; 8-prenylnaringenin, 8-PN) were tested: 8-PN was a potent inhibitor, whereas XH had no effect. Finally, estrogen-induced malignant transformation of MCF-10A cells was observed to be significantly inhibited by hops (5 μg/mL) and 8-PN (50 nmol/L). These data suggest that hops extracts possess cancer chemopreventive activity through attenuation of estrogen metabolism mediated by 8-PN.

UI MeSH Term Description Entries
D008956 Models, Chemical Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. Chemical Models,Chemical Model,Model, Chemical
D010936 Plant Extracts Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard. Herbal Medicines,Plant Extract,Extract, Plant,Extracts, Plant,Medicines, Herbal
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D002853 Chromatography, Liquid Chromatographic techniques in which the mobile phase is a liquid. Liquid Chromatography
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D004967 Estrogens Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. Estrogen,Estrogen Effect,Estrogen Effects,Estrogen Receptor Agonists,Estrogenic Agents,Estrogenic Compounds,Estrogenic Effect,Estrogenic Effects,Agents, Estrogenic,Agonists, Estrogen Receptor,Compounds, Estrogenic,Effects, Estrogen,Effects, Estrogenic,Receptor Agonists, Estrogen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L P Hemachandra, and P Madhubhani, and R Chandrasena, and P Esala, and Shao-Nong Chen, and Matthew Main, and David C Lankin, and Robert A Scism, and Birgit M Dietz, and Guido F Pauli, and Gregory R J Thatcher, and Judy L Bolton
August 2003, Toxicology and applied pharmacology,
L P Hemachandra, and P Madhubhani, and R Chandrasena, and P Esala, and Shao-Nong Chen, and Matthew Main, and David C Lankin, and Robert A Scism, and Birgit M Dietz, and Guido F Pauli, and Gregory R J Thatcher, and Judy L Bolton
September 2010, Cancer cell international,
L P Hemachandra, and P Madhubhani, and R Chandrasena, and P Esala, and Shao-Nong Chen, and Matthew Main, and David C Lankin, and Robert A Scism, and Birgit M Dietz, and Guido F Pauli, and Gregory R J Thatcher, and Judy L Bolton
May 2014, Cancer prevention research (Philadelphia, Pa.),
L P Hemachandra, and P Madhubhani, and R Chandrasena, and P Esala, and Shao-Nong Chen, and Matthew Main, and David C Lankin, and Robert A Scism, and Birgit M Dietz, and Guido F Pauli, and Gregory R J Thatcher, and Judy L Bolton
December 2014, Steroids,
L P Hemachandra, and P Madhubhani, and R Chandrasena, and P Esala, and Shao-Nong Chen, and Matthew Main, and David C Lankin, and Robert A Scism, and Birgit M Dietz, and Guido F Pauli, and Gregory R J Thatcher, and Judy L Bolton
January 2005, Journal of natural products,
L P Hemachandra, and P Madhubhani, and R Chandrasena, and P Esala, and Shao-Nong Chen, and Matthew Main, and David C Lankin, and Robert A Scism, and Birgit M Dietz, and Guido F Pauli, and Gregory R J Thatcher, and Judy L Bolton
December 2004, Journal of natural products,
L P Hemachandra, and P Madhubhani, and R Chandrasena, and P Esala, and Shao-Nong Chen, and Matthew Main, and David C Lankin, and Robert A Scism, and Birgit M Dietz, and Guido F Pauli, and Gregory R J Thatcher, and Judy L Bolton
January 2004, The breast journal,
L P Hemachandra, and P Madhubhani, and R Chandrasena, and P Esala, and Shao-Nong Chen, and Matthew Main, and David C Lankin, and Robert A Scism, and Birgit M Dietz, and Guido F Pauli, and Gregory R J Thatcher, and Judy L Bolton
February 2004, Drug metabolism and disposition: the biological fate of chemicals,
L P Hemachandra, and P Madhubhani, and R Chandrasena, and P Esala, and Shao-Nong Chen, and Matthew Main, and David C Lankin, and Robert A Scism, and Birgit M Dietz, and Guido F Pauli, and Gregory R J Thatcher, and Judy L Bolton
March 2005, Journal of mass spectrometry : JMS,
L P Hemachandra, and P Madhubhani, and R Chandrasena, and P Esala, and Shao-Nong Chen, and Matthew Main, and David C Lankin, and Robert A Scism, and Birgit M Dietz, and Guido F Pauli, and Gregory R J Thatcher, and Judy L Bolton
November 2013, Carcinogenesis,
Copied contents to your clipboard!